Home > Press > iCeutica and Nordic Biotech Sign an Agreement to Reformulate and Commercialise Nano-Compounds Using iCeutica’s EON™ Platform
Abstract:
-iCeutica Inc is pleased to announce that it has signed a binding agreement with Danish venture capital group Nordic Biotech to establish a new company Spree Pharma A/S. The agreement enables Spree to leverage iCeutica's proprietary Encapsulated Organic Nanoparticle (EON) Platform to reformulate a number of compounds for launch and marketing by Spree Pharma A/S in focused therapeutic indications.
The agreement provides for Nordic Biotech to invest in Spree Pharma A/S which will be co-owned by both iCeutica Inc and Nordic Biotech. Spree will be responsible for selection of drug compounds for reformulation using iCeutica's EON Platform and for their commercialisation. iCeutica will undertake the reformulation work under contract with Spree.
"We are happy to have started Spree Pharma A/S based on the iCeutica technology and look forward to building a therapeutically focused pharmaceutical company," said Nordic Biotech partner Florian Schönharting.
"This transaction combines iCeutica's EON Platform with the strong product development and management capabilities of Nordic," commented iCeutica CEO Matt Callahan. "This opportunity provides additional commercial opportunities for iCeutica with a highly credible player."
####
About iCeutica Inc.
iCeutica commercializes products developed by their proprietary EON™ Platform. EON is a validated enabling technology with the potential to provide low cost solutions to extending the clinically relevant life cycle of blockbuster drugs, as well as to become a cornerstone drug delivery technique for new chemical entities. The EON Platform provides a simple and scalable process to reformulate a range of different drugs.
About Nordic Biotech
Nordic Biotech Advisors was founded in 2001, and currently advises Nordic Biotech K/S and Nordic Biotech II K/S, with a combined committed capital of more than DKK 800 mill. Current portfolio companies include Curalogic A/S, Osteologix Inc., Forward Pharma A/S and Life Cycle Pharma A/S. Key Investors include Lundbeck Pharma, HBM Bioventures, Vækstfonden, Biotechnology Value Fund, LD Pensions, W Capital and the Lundbeck Foundation.
For more information, please click here
Contacts:
iCeutica Inc
by
Phoenix IP Ventures
Lisa Gray, Managing Partner
267-765-3233
Copyright © Business Wire 2007
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||